Sitagliptin hydrochloride Polymorphic form III

Sitagliptin hydrochloride Polymorphic form III
Product Description

DISCLAIMER

The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products with PIPELINE & EARLY DEVELOPMENT STATUS under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP right.

Polpharma S.A.

  • PL
  • 2015
    On CPHI since
  • 4
    Certificates
  • 5000+
    Employees
Company types
CMO/CDMO
Contract Service
Generics/Biosimilars Manufacturer
Manufacturer/Innovator
Pharmaceutical company
Specifications
  • CAS Registry Number
    486459-71-6
  • Supplied from
    Poland

Polpharma S.A.

  • PL
  • 2015
    On CPHI since
  • 4
    Certificates
  • 5000+
    Employees
Company types
CMO/CDMO
Contract Service
Generics/Biosimilars Manufacturer
Manufacturer/Innovator
Pharmaceutical company

More Products from Polpharma S.A. (34)

  • Linagliptin

    Product Linagliptin

    Linagliptin

    Mix A&B

    > White API color
    > Better impurity profile


    DISCLAIMER

    Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement. It ...
  • Elagolix sodium Amorphous form

    Product Elagolix sodium Amorphous form

    DISCLAIMER

    The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products with PIPELINE & EARLY DEVELOPMENT STATUS under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP...
  • Empagliflozin Crystalline anhydrous

    Product Empagliflozin Crystalline anhydrous

    DISCLAIMER

    The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products with PIPELINE & EARLY DEVELOPMENT STATUS under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP...
  • Linagliptin Mix of form A & B

    Product Linagliptin Mix of form A & B

    DISCLAIMER

    The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products with PIPELINE & EARLY DEVELOPMENT STATUS under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP...
  • Pimavanserin tartrate Crystalline anhydrous form C

    Product Pimavanserin tartrate Crystalline anhydrous form C

    DISCLAIMER

    The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products with PIPELINE & EARLY DEVELOPMENT STATUS under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP...
  • Rivaroxaban

    Product Rivaroxaban

    DISCLAIMER

    The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products with PIPELINE & EARLY DEVELOPMENT STATUS under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP...
  • Isavuconazole sulfate

    Product Isavuconazole sulfate

    DISCLAIMER

    The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products with PIPELINE & EARLY DEVELOPMENT STATUS under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP...
  • Enzalutamide

    Product Enzalutamide

     We provide with Anhydrous form R1

    Enzalutamide is a second-generation androgen receptor inhibitor used to treat castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of c...
  • Isavuconazole

    Product Isavuconazole

    under development
  • Sacubitril Valsartan

    Product Sacubitril Valsartan

    Crystalline polymorphic form
    Sacubitril/valsartan is the first agent to be approved in a new class of drugs called angiotensin receptor neprilysin inhibitor (ARNI). The medication is FDA-approved to treat patients with chronic heart failure with reduced ejection fraction (HFrEF) with NYHA class I...
  • Ticagrelor, Form II

    Product Ticagrelor, Form II

    DISCLAIMER Each product is protected by a patent in force in Poland and is therefore developed and manufactured solely for the purpose of Regulatory Submissions or R&D purposes. This product is not offered for sale in countries where the patent is valid and the offer or sale or any relat...
  • Acenocoumarol

    Product Acenocoumarol

    Therapeutic Area: Cardiovascular systemEU DMF available Indication: Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist

Polpharma S.A. resources (2)

  • News CPHI Barcelona 2023: Tackling the Pharma Talent Precipice – Part 2

    This year at CPHI Barcelona (24–26 October, 2023) we sat down with C-suite executives and HR professionals to discuss the looming talent crisis in the pharmaceutical industry. With hybrid working persisting post-pandemic and a growing skills gap, how can the pharmaceutical supply chain adjust to a changing labour force? 
  • Brochure API Product List 2024

    We manufacture our products by following our customers' and health authorities' most stringent requirements. DMF documentation for all our products is prepared in accordance with the latest requirements of EDQM (CEP), ICH (EuDMF, CTD), and FDA (US DMF). Material and product testing is performed in line with the European and United States Pharmacopeias.